Radium‐223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program

BACKGROUND. In the phase III ALSYMPCA trial, metastatic castration‐resistant prostate cancer (mCRPC) patients had few prior life‐prolonging therapies. Following ALSYMPCA, which demonstrated radium‐223 survival benefit, and before radium‐223 U.S. commercial availability, an expanded access program (E...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Sartor, Oliver, Vogelzang, Nicholas J., Sweeney, Christopher, Fernandez, Daniel C., Almeida, Fabio, Iagaru, Andrei, Brown, Alan, Smith, Matthew R., Agrawal, Manish, Dicker, Adam P., Garcia, Jorge A., Lutzky, Jose, Wong, Yu‐Ning, Petrenciuc, Oana, Gratt, Jeremy, Shore, Neal D., Morris, Michael J.
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2017
Témata:
Genitourinary Cancer
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5813754/
https://ncbi.nlm.nih.gov/pubmed/29183960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0413
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky